Pull up Fortress Biotech’s 2025 annual results and skip past the revenue line. Go straight to the balance sheet footnote on the priority review voucher. The number sitting there — $205 million — is not a milestone payment, not a licensing fee, and not a partnership advance. It is Fortress converting a regulatory certificate, earned through FDA approval of ZYCUBO for Menkes disease, into institutional-grade capital. In rare disease, that is the business model hiding in plain sight.
The street read this as a peripheral item. It is not peripheral. It is the architecture.
The Voucher Economy Nobody Models
Menkes disease is a copper metabolism disorder so rare that it affects roughly one in 100,000 live births in the United States. No commercial blockbuster lives in that patient population — peak sales projections for any Menkes therapy are measured in the low tens of millions, not hundreds. The FDA knows this. Congress knew it when structuring the rare pediatric disease priority review voucher program, which awards a transferable regulatory fast-track certificate to sponsors who successfully develop therapies for qualifying diseases. The certificate can then be sold to any large pharmaceutical company that needs to accelerate a separate, commercially significant NDA or BLA review.
Vouchers have historically traded at nine-figure sums, and the $205 million Fortress realized on this transaction sits at the high end of recent market comps. For context, that figure likely exceeds the cumulative R&D investment Fortress made in ZYCUBO across its development lifecycle. The drug itself becomes almost secondary to the financial instrument it generated.
Old model: develop a rare disease therapy, build a small commercial infrastructure, hope for reimbursement, wait for peak sales that never quite arrive. New model: engineer the regulatory outcome, monetize the voucher, redeploy capital into the next qualifying asset. Fortress is not alone in recognizing this — Ultragenyx and bluebird bio have both navigated the voucher market — but few companies have structured their entire rare disease portfolio around the logic as explicitly as Fortress appears to be doing.
ZYCUBO and the Commercial Realism Problem
ZYCUBO’s FDA approval for Menkes disease is a genuine scientific milestone. Menkes has had no approved therapy for decades, and the copper histidinate formulation that underlies ZYCUBO represents legitimate bench-to-approval translation. Give the science its due.
But now run the commercial math. The diagnosed Menkes population in the U.S. is in the low hundreds at any given time. Even at orphan drug pricing — which can reach into the hundreds of thousands of dollars per patient annually — the total addressable market caps out well below $100 million in peak annual revenue under the most optimistic modeling. That is before accounting for the complexity of newborn screening penetration, the neurological severity of late-diagnosed cases limiting treatment response, and the payer scrutiny that ultra-rare pricing increasingly attracts following Institute for Clinical and Economic Review challenges to similar therapies.
Fortress’s real return on ZYCUBO was always the $205 million voucher, not the product P&L.
Which raises an uncomfortable question for the rare disease sponsors who are building their enterprise value narratives around orphan drug pricing power alone: if the voucher monetization is the primary capital event, what happens to your strategy when Congress revisits the program’s economics — as it has considered doing multiple times — or when buyer demand from large pharma softens because their own pipelines thin out?
Who Gets Repriced, Who Gets Rewarded
Fortress’s 2025 results position it as a potential model for mid-cap rare disease operators — but the model only works if the pipeline keeps qualifying. The rare pediatric disease designation requires the target condition to affect fewer than 200,000 U.S. patients annually and to be serious or life-threatening. That is a relatively narrow funnel, and Fortress will need continued regulatory designation wins across its subsidiary portfolio to sustain the voucher strategy beyond ZYCUBO.
The competitive read here cuts against pure-play rare disease biotechs that are pricing themselves on projected orphan drug revenues without modeling the voucher optionality explicitly. Companies like Passage Bio and Rocket Pharmaceuticals, both operating in ultra-rare neurological and hematological indications with gene therapy platforms, are sitting on potential voucher-generating assets but have not publicly framed their investor narratives around voucher monetization as a capital strategy. That is a valuation gap a sophisticated BD&L team could arbitrage.
On the losing side of this signal: large pharma buyers of vouchers face a seller’s market if more Fortress-style operators begin systematically manufacturing qualifying approvals. The $205 million Fortress received reflects supply scarcity. Increase the supply of vouchers through coordinated rare disease development programs, and the clearing price compresses. Eli Lilly, AstraZeneca, and other large-cap sponsors that have historically purchased vouchers to protect late-stage commercial timelines will eventually face either higher acquisition costs or longer standard review windows — neither is free.
Fortress itself carries execution risk that the voucher headline obscures. Its subsidiary model — holding stakes in multiple publicly traded and private biotechs including Avenue Therapeutics and Mustang Bio — creates a complex consolidated balance sheet where the $205 million in voucher proceeds must be read against parent-level liabilities and subsidiary cash burn rates. The 2025 annual results, filed with the SEC, will show whether that capital is being deployed into the next qualifying pipeline or absorbed by operational overhead.
The Signal to Watch
If you are a rare disease biotech with a Phase 2 asset in a qualifying pediatric indication, the Fortress ZYCUBO-to-voucher conversion just demonstrated that your risk-adjusted NPV calculation has a missing line item. Model the voucher. Price it at current market comps. Then ask your BD&L counterpart why it is not already part of your partnering pitch.
The next signal to watch is whether the buyer of the Fortress voucher — whose identity has not been publicly disclosed — uses it to accelerate an NDA in a blockbuster indication. When that approval lands, and the timeline compression becomes visible in the FDA’s action date record, the market will finally understand what Fortress sold: not a regulatory certificate, but a year of commercial runway for someone else’s multibillion-dollar product. At that point, the $205 million will look like a discount.
